|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5242824A
(en)
|
1988-12-22 |
1993-09-07 |
Oncogen |
Monoclonal antibody to human carcinomas
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
GB9014932D0
(en)
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
|
US5889157A
(en)
|
1990-10-12 |
1999-03-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Humanized B3 antibody fragments, fusion proteins, and uses thereof
|
|
US5608039A
(en)
|
1990-10-12 |
1997-03-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Single chain B3 antibody fusion proteins and their uses
|
|
US5846535A
(en)
|
1990-10-12 |
1998-12-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity
|
|
US5981726A
(en)
|
1990-10-12 |
1999-11-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5874540A
(en)
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
EP0970227B1
(en)
|
1997-03-20 |
2008-01-09 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
|
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
ATE296315T1
(de)
|
1997-06-24 |
2005-06-15 |
Genentech Inc |
Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
US6809184B1
(en)
|
1997-12-01 |
2004-10-26 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
DK1180123T3
(da)
|
1999-05-27 |
2008-10-13 |
Us Gov Health & Human Serv |
Immunkonjugater, der har höj bindingsaffinitet
|
|
JP2003505082A
(ja)
|
1999-07-26 |
2003-02-12 |
ジェネンテック・インコーポレーテッド |
新規なポリヌクレオチドとその使用法
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
CN100427603C
(zh)
|
1999-10-04 |
2008-10-22 |
麦迪卡格公司 |
调控外源基因转录的方法
|
|
WO2002040545A2
(en)
|
2000-11-17 |
2002-05-23 |
The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services |
Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
|
|
EP2180044A1
(en)
|
2001-08-03 |
2010-04-28 |
GlycArt Biotechnology AG |
Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
|
|
CA2461351C
(en)
|
2001-09-26 |
2014-08-05 |
Ira H. Pastan |
Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
|
|
HUP0600342A3
(en)
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
|
US20040259150A1
(en)
|
2002-04-09 |
2004-12-23 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
|
|
JP4832719B2
(ja)
|
2002-04-09 |
2011-12-07 |
協和発酵キリン株式会社 |
ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
|
|
EA200401325A1
(ru)
|
2002-04-09 |
2005-04-28 |
Киова Хакко Когио Ко., Лтд. |
Клетки с модифицированным геномом
|
|
US20040132140A1
(en)
|
2002-04-09 |
2004-07-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
|
WO2003104432A2
(en)
|
2002-06-07 |
2003-12-18 |
The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins
|
|
US7232888B2
(en)
|
2002-07-01 |
2007-06-19 |
Massachusetts Institute Of Technology |
Antibodies against tumor surface antigens
|
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
|
EP3263596A1
(en)
|
2002-12-16 |
2018-01-03 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
CN103540600B
(zh)
|
2003-01-22 |
2017-12-01 |
罗氏格黎卡特股份公司 |
融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US7982011B2
(en)
|
2003-11-25 |
2011-07-19 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated anti-cd22 antibodies and immunoconjugates
|
|
KR100891620B1
(ko)
|
2004-04-13 |
2009-04-02 |
에프. 호프만-라 로슈 아게 |
항-ｐ-셀렉틴 항체
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
AU2006211037B2
(en)
|
2005-02-07 |
2012-05-24 |
Roche Glycart Ag |
Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
|
|
CA2633756C
(en)
|
2005-12-21 |
2015-11-24 |
Micromet Ag |
Pharmaceutical antibody compositions with resistance to soluble cea
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
ES2563027T3
(es)
*
|
2008-01-07 |
2016-03-10 |
Amgen Inc. |
Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
|
|
WO2010099536A2
(en)
*
|
2009-02-27 |
2010-09-02 |
Massachusetts Institute Of Technology |
Engineered proteins with high affinity for dota chelates
|
|
KR20120108967A
(ko)
|
2009-09-16 |
2012-10-05 |
제넨테크, 인크. |
코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
|
|
RS56793B1
(sr)
|
2011-03-02 |
2018-04-30 |
Roche Glycart Ag |
Cea antitela
|
|
SG10201602394QA
(en)
|
2011-03-29 |
2016-05-30 |
Roche Glycart Ag |
Antibody FC Variants
|
|
MY169358A
(en)
*
|
2011-08-23 |
2019-03-26 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
PT2802607T
(pt)
*
|
2012-01-13 |
2018-01-03 |
Univ Wuerzburg J Maximilians |
Complementação funcional bipartida induzida por duplo antigénio
|
|
CA2860600C
(en)
|
2012-02-15 |
2022-07-26 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
|
MX375359B
(es)
|
2013-02-26 |
2025-03-06 |
Roche Glycart Ag |
Moléculas biespecíficas de unión a antígeno activadoras de células t.
|
|
KR20210094669A
(ko)
|
2013-04-29 |
2021-07-29 |
에프. 호프만-라 로슈 아게 |
인간 fcrn-결합 변형된 항체 및 사용 방법
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
MY193723A
(en)
*
|
2014-08-29 |
2022-10-27 |
Hoffmann La Roche |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
CR20170194A
(es)
|
2014-11-14 |
2017-07-10 |
Hoffmann La Roche |
Moleculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf
|
|
AU2016252773B2
(en)
|
2015-04-24 |
2022-06-02 |
Genentech, Inc. |
Multispecific antigen-binding proteins
|
|
EP3356410B1
(en)
|
2015-10-02 |
2021-10-20 |
F. Hoffmann-La Roche AG |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
|
ES2873846T5
(en)
*
|
2015-11-19 |
2025-06-23 |
Revitope Ltd |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
|
GB201521391D0
(en)
*
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
WO2019094626A1
(en)
*
|
2017-11-08 |
2019-05-16 |
Fred Hutchinson Cancer Research Center |
Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies
|
|
WO2019122350A1
(en)
*
|
2017-12-21 |
2019-06-27 |
Gernot Stuhler |
Specific dosage regimen for hemibody therapy
|
|
EP3781201B8
(en)
*
|
2018-04-16 |
2025-10-15 |
Orano Med Manufacturing SAS |
Antibodies for chelated radionuclides and clearing agents
|
|
JP7475283B2
(ja)
*
|
2018-04-16 |
2024-04-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
キレート化された放射性核種に対する抗体
|
|
WO2020007817A1
(en)
*
|
2018-07-04 |
2020-01-09 |
F. Hoffmann-La Roche Ag |
Novel bispecific agonistic 4-1bb antigen binding molecules
|
|
AR119382A1
(es)
*
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|